

B. Amendments to the Claims

{Please amend the claims as follows:}

1. (Currently amended) A peptide which is a hydrophilic analog of an alpha-fetoprotein having SEQ ID NO:6ef, wherein said peptide has antiestrotrophic activity and is eight to twenty amino acids long in length which comprises a hydrophilic analog of an alpha-fetoprotein peptide having SEQ ID NO:6: EMTPVNPG.
2. (Currently amended) The peptide of claim 1, wherein ~~the~~ said peptide is linear.
3. (Currently amended) The peptide of claim 1, wherein ~~the~~ said peptide is cyclic.
4. (Currently amended) The peptide of claim 1, wherein one or more of ~~the~~ said amino acids is a (D)-amino acid.
5. (Currently amended) The peptide of claim 1, ~~which comprises an~~ wherein the amino acid sequence of said peptide is selected from the group consisting of:

SEQ ID NO:2: ~~Q~~MTPVNPG
SEQ ID NO:3: ~~Q~~MTPVNPGE
SEQ ID NO:4: EMTOVNOG
SEQ ID NO:5: EMTOVNOGQ
~~SEQ ID NO:7: EMTPVNPGQ~~
SEQ ID NO:8: EMTOVNPG
SEQ ID NO:9: EMTOVNPGQ
SEQ ID NO:10: EMTPVNOG and
SEQ ID NO:11: EMTPVNOGQ,

or a peptidomimetic of said peptide.

6. (Original) The peptide of claim 1 labeled with a detectable marker.
7. (Original) The peptide of claim 6 wherein the detectable marker is a radiolabel.
8. (Original) The peptide of claim 7 wherein the radiolabel is a radiolabeled additional amino acid.
9. (Currently amended) A dimeric peptide consisting of two peptides of [claim 1] eight to twenty amino acids in length which comprises a hydrophilic analog of an alpha-fetoprotein peptide having SEQ ID NO:6: EMTPVNPG.
10. (Currently amended) The dimeric peptide of claim 9, wherein the two said peptides are SEQ ID NO:4 and SEQ ID NO:5.

11. (Currently amended) The dimeric peptide of claim 10, wherein the two said peptides are
SEQ ID NO:3 and SEQ ID NO:10.

12. (Original) A multimeric peptide consisting of three or more peptides of claim 1.

13-15. (Canceled herein)

16-22. (Withdrawn)
